MCID: SPC010
MIFTS: 41

Speech and Communication Disorders malady

Categories: Mental diseases

Aliases & Classifications for Speech and Communication Disorders

Aliases & Descriptions for Speech and Communication Disorders:

Name: Speech and Communication Disorders 39 41
Communication Disorder 39 12 14
Language Disorders 52 42 69
Language Disorder 39 12 14
Communication Disorders 52 42
Speech and Language Disorder 69
Speech Language Disorder 39
Communication Impairment 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2033 DOID:93
ICD10 33 F80.9
NCIt 47 C2958 C97155

Summaries for Speech and Communication Disorders

MedlinePlus : 41 many disorders can affect our ability to speak and communicate. they range from saying sounds incorrectly to being completely unable to speak or understand speech. causes include hearing disorders and deafness voice problems, such as dysphonia or those caused by cleft lip or palate speech problems like stuttering developmental disabilities learning disorders autism spectrum disorder brain injury stroke some speech and communication problems may be genetic. often, no one knows the causes. by first grade, about 5 percent of children have noticeable speech disorders. speech and language therapy can help. nih: national institute on deafness and other communication disorders

MalaCards based summary : Speech and Communication Disorders, also known as communication disorder, is related to cluttering and mixed receptive-expressive language disorder, and has symptoms including lethargy, neurobehavioral manifestations and aprosodia. An important gene associated with Speech and Communication Disorders is FOXP2 (Forkhead Box P2), and among its related pathways/superpathways are Neuroscience and Alzheimers Disease Pathway. The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are cellular and no phenotypic analysis

Disease Ontology : 12 A specific developmental disorder that involves specific developmental disorders of speech and language.

Wikipedia : 71 A communication disorder is any disorder that affects an individual\'s ability to comprehend, detect, or... more...

Related Diseases for Speech and Communication Disorders

Diseases related to Speech and Communication Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 cluttering 10.8
2 mixed receptive-expressive language disorder 10.7
3 speech disorder 10.7
4 usher syndrome 10.5
5 stuttering 10.5
6 expressive language disorder 10.5
7 acoustic neuroma 10.5
8 agnosia 10.5
9 meniere's disease 10.5
10 childhood apraxia of speech 10.5
11 swallowing disorders 10.5
12 protein r deficiency 10.4 GRN MAPT
13 keratosis palmoplantaris striata 10.4 APOE MAPT
14 mcleod neuroacanthocytosis syndrome 10.3 MAPT PSEN1
15 social emotional agnosia 10.3 GRN PSEN1 TARDBP
16 gata1-related thrombocytopenia 10.3 GRN MAPT PSEN1
17 hereditary paraganglioma-pheochromocytoma syndromes 10.3 GRN MAPT PSEN1
18 color agnosia 10.3 GRN PSEN1 TARDBP
19 cerebral arteritis 10.3 FOXP2 PSEN1 TARDBP
20 autoimmune disease of blood 10.3 GRN PSEN1 TARDBP
21 hyperglycemia 10.3 CBS GRN PSEN1
22 femoral neuropathy 10.3 CNTNAP2 GRN MAPT
23 cholesterol pneumonia 10.3 CNTNAP2 FOXP2
24 meckel syndrome 10 10.3 APOE MAPT PSEN1
25 pancreatitis 10.3 GRN PSEN1
26 glucose metabolism disease 10.3 CNTNAP2 FOXP2 GNPTG
27 tactile agnosia 10.3 APOE SMUG1
28 hypoproteinemia, hypercatabolic 10.3 C9orf72 MAPT TARDBP
29 scoliosis 10.3 CNTNAP2 FOXP2 GNPTG
30 pediatric mesenchymal chondrosarcoma 10.3 CBS GRN PSEN1 TARDBP
31 mechanical entropion 10.3 APOE KANTR
32 meier-gorlin syndrome 5 10.3 APOE CBS GRN MAPT
33 cerebroretinal vasculopathy 10.3 C9orf72 GRN MAPT PSEN1
34 acne inversa, familial, 3 10.3 APOE MAPT PSEN1 TARDBP
35 contagious pustular dermatitis 10.3 APOE MAPT PSEN1
36 mitochondrial dna depletion syndrome 3 10.2 C9orf72 GRN MAPT TARDBP
37 riedel's fibrosing thyroiditis 10.2 KANTR MAPT TARDBP
38 scrub typhus 10.2 ATP2C2 CNTNAP2 FOXP2 KIAA0319
39 urethritis 10.2 APOE KANTR PSEN1 TARDBP
40 mucopolysaccharidosis iv 10.2 C9orf72 GRN MAPT TARDBP
41 epithelioid type angiomyolipoma 10.2 APOE MAPT PSEN1 TARDBP
42 postauricular lymphadenitis 10.2 CBS GRN MAPT PSEN1 TARDBP
43 encephalitozoonosis 10.2 APOE CBS GRN MECP2 PSEN1
44 sexual disorder 10.2 CNTNAP2 FOXP2 MECP2
45 sideroblastic anemia 10.2 KIAA0319 MAPT MECP2
46 andersen syndrome 10.2 C9orf72 GRN MAPT PSEN1 TARDBP
47 pancreatic cancer/melanoma syndrome 10.2 C9orf72 CBS GRN PSEN1 TARDBP
48 impaired renal function disease 10.2 APOE SMUG1
49 personality disorder 10.2 APOE GRN MAPT MECP2 PSEN1
50 hallucinogen abuse 10.2 CBS KANTR

Graphical network of the top 20 diseases related to Speech and Communication Disorders:



Diseases related to Speech and Communication Disorders

Symptoms & Phenotypes for Speech and Communication Disorders

UMLS symptoms related to Speech and Communication Disorders:


lethargy, neurobehavioral manifestations, aprosodia, reduced consciousness/confusion, other symbolic dysfunction

MGI Mouse Phenotypes related to Speech and Communication Disorders:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.7 APOE C9orf72 CNTNAP2 GRN L1CAM MAPT
2 no phenotypic analysis MP:0003012 9.17 APOE C9orf72 GRN L1CAM MAPT MECP2

Drugs & Therapeutics for Speech and Communication Disorders

Drugs for Speech and Communication Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 708)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4,Phase 2,Phase 3 59-92-7 6047
3
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
6
Sertraline Approved Phase 4,Phase 2,Phase 3 79617-96-2 68617
7
Benzocaine Approved Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
8
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
9 Piracetam Approved Phase 4,Phase 1 7491-74-9
10
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
11
Minocycline Approved, Investigational Phase 4,Phase 2 10118-90-8 5281021
12
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
13
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
14
Nicotine Approved Phase 4,Phase 3,Phase 1,Phase 2 54-11-5 942 89594
15
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
16
Lorazepam Approved Phase 4,Phase 3 846-49-1 3958
17
Haloperidol Approved Phase 4 52-86-8 3559
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
20
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
21
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
22
Citalopram Approved Phase 4 59729-33-8 2771
23
Norepinephrine Approved Phase 4 51-41-2 439260
24
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
25
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
26
Carbidopa Approved Phase 4,Phase 2,Phase 3 28860-95-9 34359 38101
27
Copper Approved Phase 4,Phase 1,Phase 2 15158-11-9, 7440-50-8 27099
28
Iron Approved Phase 4,Phase 2 7439-89-6 23925
29
Selenium Approved, Vet_approved Phase 4 7782-49-2
30
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
31
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
32
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
33
Difluprednate Approved Phase 4 23674-86-4 443936
34
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
36
Milnacipran Approved Phase 4 92623-85-3 65833
37
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
38
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
39
Armodafinil Approved, Investigational Phase 4 112111-43-0
40
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
41
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
42
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
43
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
44
Emtricitabine Approved, Investigational Phase 4,Phase 1,Phase 2 143491-57-0 60877
45
Tenofovir Approved, Investigational Phase 4,Phase 1,Phase 2 147127-20-6 464205
46
Artesunate Approved Phase 4 88495-63-0 6917864 5464098
47
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 1 75330-75-5 53232
48
Trimethobenzamide Approved Phase 4 138-56-7 5577
49
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
50
Amantadine Approved Phase 4,Phase 2,Phase 3 768-94-5 2130

Interventional clinical trials:

(show top 50) (show all 3151)
id Name Status NCT ID Phase
1 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Unknown status NCT00111371 Phase 4
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4
3 Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study Unknown status NCT00956696 Phase 4
4 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4
5 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
6 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
7 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
8 The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients Unknown status NCT02361307 Phase 4
9 Bilateral Cochlear Implant Benefit in Young Children Unknown status NCT00424307 Phase 4
10 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4
11 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
12 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4
13 Omega 3/6 Fatty Acids for Reading in Children Completed NCT02557477 Phase 4
14 Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke Completed NCT02473432 Phase 4
15 Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment Completed NCT00191555 Phase 4
16 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4
17 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Completed NCT00191906 Phase 4
18 Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4
19 Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Completed NCT00607919 Phase 4
20 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4
21 Effects of Atomoxetine on Brain Activation During Attention and Reading Tasks in Patients With ADHD & Comorbid Dyslexia Completed NCT00716274 Phase 4
22 Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Completed NCT00191048 Phase 4
23 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4
24 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4
25 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4
26 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4
27 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
28 Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program Completed NCT00401726 Phase 4
29 A Clinical Trial Of Two Educational Strategies In Cardiovascular Health In Child Population Completed NCT01418872 Phase 4
30 Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan Completed NCT01552954 Phase 4
31 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
32 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4
33 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia Completed NCT01851863 Phase 4
34 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact Completed NCT00141518 Phase 4
35 Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial Completed NCT02061280 Phase 4
36 Relaxation Response Training for the Treatment of Rheumatoid Arthritis Completed NCT00056667 Phase 4
37 Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months Completed NCT02280330 Phase 4
38 Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED) Completed NCT02254304 Phase 4
39 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed NCT00545363 Phase 4
40 Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes Completed NCT02252965 Phase 4
41 SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis. Completed NCT00545480 Phase 4
42 BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis Completed NCT00545909 Phase 4
43 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4
44 Combination Nicotine Replacement for Alcoholic Smokers Completed NCT00064844 Phase 4
45 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4
46 Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids Completed NCT01378689 Phase 4
47 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4
48 Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Completed NCT01244334 Phase 4
49 A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years Completed NCT00638092 Phase 4
50 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. Completed NCT01694108 Phase 4

Search NIH Clinical Center for Speech and Communication Disorders

Cochrane evidence based reviews: communication disorders

Genetic Tests for Speech and Communication Disorders

Anatomical Context for Speech and Communication Disorders

MalaCards organs/tissues related to Speech and Communication Disorders:

39
Brain

Publications for Speech and Communication Disorders

Variations for Speech and Communication Disorders

Expression for Speech and Communication Disorders

Search GEO for disease gene expression data for Speech and Communication Disorders.

Pathways for Speech and Communication Disorders

Pathways related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.61 APOE CNTNAP2 MAPT MECP2 PSEN1 TARDBP
2 10.79 APOE MAPT PSEN1

GO Terms for Speech and Communication Disorders

Cellular components related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth cone GO:0030426 9.5 L1CAM MAPT PSEN1
2 axon GO:0030424 9.46 CNTNAP2 L1CAM MAPT PSEN1
3 dendrite GO:0030425 9.35 APOE CNTNAP2 L1CAM MAPT PSEN1
4 axolemma GO:0030673 9.26 CNTNAP2 MAPT
5 neuronal cell body GO:0043025 9.02 APOE CNTNAP2 L1CAM MAPT PSEN1

Biological processes related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 post-embryonic development GO:0009791 9.54 FOXP2 MECP2 PSEN1
2 cerebral cortex development GO:0021987 9.43 CNTNAP2 FOXP2 PSEN1
3 memory GO:0007613 9.33 MAPT MECP2 PSEN1
4 amyloid precursor protein metabolic process GO:0042982 9.32 APOE PSEN1
5 vocal learning GO:0042297 8.96 CNTNAP2 FOXP2
6 neuron projection development GO:0031175 8.92 CNTNAP2 L1CAM MAPT MECP2

Molecular functions related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001078 9.13 FOXP2 MECP2 NFXL1
2 lipoprotein particle binding GO:0071813 8.62 APOE MAPT

Sources for Speech and Communication Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....